ClinicalTrials.gg
RecruitingNCT06629103GOBOUpdated Sep 9, 2026

A Study in Healthy Subjects to Compare the Bioavailability of EPA + DHA

A Phase 4 interventional study of life's Omega 1035DS and Fish Oil in Optimal Absorption of Omega-3 and Healthy, sponsored by RDC Clinical Pty Ltd. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by RDC Clinical Pty Ltd · Phase 4, Interventional, and Other

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

This is a randomised, double-blind, parallel, placebo-controlled study in healthy subjects to compare the absorption of two microalgal formulations, to a fish oil and a placebo.

02

Conditions studied

  • Optimal Absorption of Omega-3
  • Healthy
03

In context

Lead sponsor

RDC Clinical Pty Ltd is the lead sponsor of 34 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written obtained before any trial related assessments are performed.
  2. 2. Healthy adult females ages 18-64 who are neither pregnant nor breastfeeding or healthy adult males ages 18-64 at the time of consent.

    a. Female participants of (females who are , i.e., when there has been no menstruation for a minimum of 12 months prior to screening, are considered not to be of child-bearing potential), who are not surgically sterilized, must have a negative pregnancy test at screening and be willing to practice one of the following appropriate methods until the last visit: i. Sexual abstinence. ii. Oral contraceptives. iii. Trans dermal patches or depot injection of a progestogen drug (starting at least 4 weeks prior to product administration).

    iv. Intrauterine device (IUD), intrauterine system (IUS), subdermal implant, or vaginal ring (placed at least 4 weeks prior to product administration).

    Contraceptives must be effective before the randomization visit.

  3. Participant's (BMI) must be between 18 and 30 kg/m2 (inclusive) and considered to be of healthy weight in the opinion of the investigator.
  4. Intakes of EPA+DHA of less than 300mg per day based on the FFQ

6. Agree not to change current diet and exercise frequency or intensity during entire study period

Exclusion criteria

Exclusion criteria:

  1. Participant has any health conditions that would prevent from fulfilling the study requirements, put the participant at risk or would confound the interpretation of the study results as judged by the Investigator based on medical history and routine laboratory test results.
  2. History or presence of cardiovascular, pulmonary, hepatic, renal, haematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results.
  3. Has a clinically significant abnormal finding on the medical assessment, medical history, vital signs or clinical laboratory results at screening.
  4. History or presence of allergic or adverse response to omega-3-acid ethyl esters or triglycerides (EPA or DHA), or related drugs, or sensitivity or allergy to fish or shellfish, or soybean or corn.
  5. History of coagulation disorder or current anticoagulation therapy.
  6. Has been on a significantly abnormal* diet, as deemed by the investigator, during the 4 weeks preceding the first dose of study medication. *an abnormal diet will be considered if the participant has elected to change to a more or less restricted diet of any description (e.g., change to or from a vegetarian, vegan, gluten-free, lactose-free, etc.) or significantly increases or decreases their daily caloric intake.
  7. Has participated in another clinical trial (randomised participants only) within 30 days prior to the first dose of study medication.
  8. Has used prescription medication (excluding oral and hormonal replacement therapy) within 4 weeks of screening or OTC medication within 7 days before the first dose that may affect omega-3 absorption or any study outcomes. This may include but is not limited to: high-dose NSAIDs, bile acid sequestrants, statins, GLP-1 receptor agonists, anticoagulants and anti-inflammatory drugs. Occasional ibuprofen, paracetamol and low-dose aspirin use is permitted.
  9. Regular use* of omega-3 supplements and/or regular fatty fish consumption within 2 months. *Regular use is defined as more than once per week of either fish oil, krill oil, microalgal oil supplements, or fatty fish.
  10. Has smoked or used tobacco products within 60 days prior to the first dose of study medication.
  11. History of substance abuse or treatment (including more than 14 alcoholic drinks per week) within the past 2 years based on the judgement of the investigator.
  12. Has a positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, opiates).
  13. Has increased bleeding from existing pathological conditions or anticipates surgery (including dental) prior to, throughout, or within 1 week after study participation.
  14. Has had a (TIA) or stroke or is at high risk for recurrent ischemic events.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    life's Omega 1035DS

    Dietary Supplement: life's Omega 1035DS

  • Active comparator
    life'sTM Omega O3020DS

    Dietary Supplement: life's Omega O3020DS

  • Active comparator
    MEG-3TM 1812 TG

    Dietary Supplement: Fish Oil

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Dietary supplementlife's Omega 1035DS

    A natural triglyceride derived from microalgae with minimum 365 mg DHA, minimum 100 mg EPA, and minimum 520 mg/g DHA + EPA. Participants receive 600mg/d of omega-3 fatty acids from the microalgal oil.

  • Dietary supplementFish OilsStudies of Fish OilsFish Oils pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Commercially available fish oil product MEG-3 1812 TG with a minimum 100 mg DHA/capsule, minimum 160 mg EPA/capsule, and minimum 300 mg/g DHA+EPA. Participants receive 600mg/d of omega-3 fatty acids from the fish oil.

  • OtherPlacebo

    The placebo capsules will be a mixture of corn and soybean oils. Participants receive 600mg/d of omega-3 fatty acids from the corn/soy placebo.

  • Dietary supplementlife's Omega O3020DS

    A natural triglyceride derived from microalgae with minimum 210 mg DHA, minimum 300 mg EPA, and minimum 510 mg/g DHA + EPA. Participants receive 600mg/d of omega-3 fatty acids from the microalgal oil.

06

What researchers measure

Primary outcomes

  1. To compare the bioavailability of 600 mg/day of Omega-3 fatty acids (EPA+DHA) from two microalgal sources to a fish source by comparing the change from baseline in the sum level of EPA and DHA in plasma phospholipids across all treatments.

    The change in plasma phospholipids EPA+DHA µg/ml levels from baseline to week 6 between MEG-3, O1035DS and O3020DS and placebo as determined by Gas Chromatography (GC).

    Time frame: 6 weeks

Secondary outcomes

  1. To compare the bioavailability by 600mg/day of Omega-3 fatty acids by comparing the change from baseline in the sum level of EPA and DHA in plasma phospholipids across all treatments at the end of a 2, 4, and 6 week supplementation study.

    The change in plasma phospholipids EPA+DHA µg/ml levels from baseline to week 2, 4, and 6 between MEG-3, O1035DS, O3020DS and placebo as determined by Gas Chromatography (GC).

    Time frame: 2, 4 and 6 weeks

  2. To compare the bioavailability of 600mg/day of Omega-3 fatty acids by comparing the change from baseline in Omega-3 Index across all treatments at the end of a 6 week supplementation study.

    The change in the Omega-3 Index (percent of EPA + DHA in red blood cell membranes) from baseline to week 6 between MEG-3, O1035DS, O3020DS and placebo as determined by Gas Chromatography (GC).

    Time frame: 6 weeks

  3. To compare the bioavailability of 600mg/day Omega-3 fatty acids by comparing the change from baseline in the plasma phospholipid levels across all treatments at week 2 and week 4 of supplementation.

    The change in plasma phospholipids EPA+DHA µg/ml levels from baseline to week 2 and baseline to week 4 between MEG-3, O1035DS, O3020DS and placebo as determined by Gas Chromatography (GC).

    Time frame: 2 and 4 weeks

  4. To compare the changes from baseline in lipoprotein levels following consumption of the microalgal oils, fish oil or placebo at the end of a 6-week supplementation study.

    The change in total cholesterol, HDL- and LDL-cholesterol and triglyceride levels from baseline to week 6 between MEG-3, O1035DS, O3020DS and placebo as determined by a clinical analyser.

    Time frame: 6 weeks

Other outcomes

  1. Additional endpoint 1

    Change from baseline in plasma phospholipid EPA at weeks 2, 4 and 6 in MEG-3, O3020DS, 1035DS and placebo adjusted for intake level.

    Time frame: 2, 4 and 6 weeks

  2. Additional endpoint 2

    Change from baseline in plasma phospholipid DHA at weeks 2, 4 and 6 in MEG-3, O3020DS, 1035DS and placebo adjusted for intake level.

    Time frame: 2, 4 and 6 weeks

  3. Additional endpoint 3 - Cytokines

    Exploratory parameters (Cytokines) at baseline and week 6 will be analysed using ELISA.

    Time frame: Baseline and 6 weeks

  4. Additional endpoint 3 - neurotransmitters

    Exploratory parameters (neurotransmitters) at baseline and week 6 will be analysed using ELISA.

    Time frame: Baseline and 6 weeks

  5. Additional endpoint 3 - specialized pro-resolving mediators

    Exploratory parameters (specialized pro-resolving mediators) at baseline and week 6 will be analysed using ELISA.

    Time frame: Baseline and 6 weeks

  6. Additional endpoint 3 - PhenoAge Accel Index

    Exploratory parameters (PhenoAge Accel Index) at baseline and week 6. This is a metric calculated from phenotypic and chronological age, albumin, creatinine, alkaline phosphatase, glycated haemoglobin, WBC count, lymphocyte percentage, haemoglobin, red cell distribution width, MCV and, glucose).

    Time frame: Baseline and 6 weeks

  7. Additional endpoint 3 - Aging clock (iAge)

    Exploratory parameters (Aging Clock) at baseline and week 6. This is a metric calculated from CXCL9, CCL11, CCL3, leptin, IL-1beta, IL-5, IFN-alpha, IFN-gamma, IL-4.

    Time frame: Baseline and 6 weeks

  8. Additional endpoint 3 - PhenoAge Clock

    Exploratory parameters (PhenoAge Clock) at baseline and week 6. An epigenetic clock comprised of DNA methylation (DNAm) algorithms that combine information from measurements across the genome to quantify variations in biological versus chronological aging.

    Time frame: Baseline and 6 weeks

  9. Additional endpoint 3 - Brain Health Score

    Exploratory parameters (Brain Health Score) at baseline and week 6. Brain health score derived from plasma proteomic and metabolomic biomarkers .

    Time frame: Baseline and 6 weeks

  10. Safety Endpoint 1

    Screening and final visit clinical chemistry (electrolytes and liver function tests) and haematology (full blood counts) profiles will be assessed by clinical analyser.

    Time frame: 6 weeks

  11. Safety Endpoint 2

    Vital signs: Blood pressure (BP) will be assessed at screening, baseline and final visit.

    Time frame: 6 weeks

  12. Safety Endpoint 2

    Vital signs: Heart rate (HR) will be assessed at screening and final visit.

    Time frame: 6 weeks

  13. Safety Endpoint 2

    Vital signs: Body temperature will be assessed at screening and final visit.

    Time frame: 6 weeks

  14. Safety Endpoint 3

    Anthropometric: Weight (kg) will be assessed at screening, baseline and the final visit.

    Time frame: Baseline to 6 weeks

  15. Safety Endpoint 3

    Anthropometric: Waist-hip-ratio (WHR) will be assessed at screening and the final visit.

    Time frame: 6 weeks

  16. Safety Endpoint 4

    Adverse event (AE) listing will be collected.

    Time frame: 6 weeks

  17. Safety Endpoint 5

    Serious Adverse Event (SAE) will be reported to HREC, United BioSource Corporation (UBC) in Geneva, and the sponsor.

    Time frame: 6 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Apr 2027, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2024
First posted
Oct 8, 2024
StartActual
Aug 6, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06629103
Responsible party
Sponsor
First posted
Oct 8, 2024
Start date
Aug 6, 2025
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Sep 9, 2026

Study contacts

David Briskey
Contact
david@rdcglobal.com.au
+61 (0) 7 3102 4486
Anne Birkett
study director · dsm-firmenich Switzerland AG

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fish Oils

Start the discussion